Literature DB >> 28135565

Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.

Courtney L Monroe1, Sonika Dahiya2, David H Gutmann1.   

Abstract

Neurofibromatosis type 1 (NF1) is a common neurogenetic disorder in which affected children and adults are predisposed to the development of benign and malignant nervous system tumors. Caused by a germline mutation in the NF1 tumor suppressor gene, individuals with NF1 are prone to optic gliomas, malignant gliomas, neurofibromas, and malignant peripheral nerve sheath tumors, as well as behavioral, cognitive, motor, bone, cardiac, and pigmentary abnormalities. Although NF1 is a classic monogenic syndrome, the clinical features of the disorder and their impact on patient morbidity are variable, even within individuals who bear the same germline NF1 gene mutation. As such, NF1 affords unique opportunities to define the factors that contribute to disease heterogeneity and to develop therapies personalized to a given individual (precision medicine). This review highlights the clinical features of NF1 and the use of genetically engineered mouse models to define the molecular and cellular pathogenesis of NF1-associated nervous system tumors.

Entities:  

Keywords:  NF1; brain tumors; neurofibroma; optic pathway glioma; precision medicine

Mesh:

Year:  2017        PMID: 28135565     DOI: 10.1146/annurev-pathol-052016-100228

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  18 in total

1.  Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.

Authors:  Shiyang Wang; Benjamin Liechty; Seema Patel; Jeffrey S Weber; Travis J Hollmann; Matija Snuderl; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

2.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

3.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.

Authors:  Chung-Ping Liao; Reid C Booker; Jean-Philippe Brosseau; Zhiguo Chen; Juan Mo; Edem Tchegnon; Yong Wang; D Wade Clapp; Lu Q Le
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

4.  Large Scale Identification of Variant Proteins in Glioma Stem Cells.

Authors:  Ekaterina Mostovenko; Ákos Végvári; Melinda Rezeli; Cheryl F Lichti; David Fenyö; Qianghu Wang; Frederick F Lang; Erik P Sulman; K Barbara Sahlin; György Marko-Varga; Carol L Nilsson
Journal:  ACS Chem Neurosci       Date:  2017-12-21       Impact factor: 4.418

5.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

6.  Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.

Authors:  Andrea M Gross; Gurbani Singh; Srivandana Akshintala; Andrea Baldwin; Eva Dombi; Somto Ukwuani; Anne Goodwin; David J Liewehr; Seth M Steinberg; Brigitte C Widemann
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

7.  Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients.

Authors:  Teresa Esposito; Carla Schettino; Paola Polverino; Salvatore Allocca; Laura Adelfi; Alessandra D'Amico; Guglielmo Capaldo; Bruno Varriale; Anna Di Salle; Gianfranco Peluso; Giuseppe Sorrentino; Giacomo Lus; Simone Sampaolo; Giuseppe Di Iorio; Mariarosa Anna Beatrice Melone
Journal:  Nutrients       Date:  2017-07-21       Impact factor: 5.717

8.  The investigation for potential modifier genes in patients with neurofibromatosis type 1 based on next-generation sequencing.

Authors:  Fan Yang; Song Xu; Renwang Liu; Tao Shi; Xiongfei Li; Xuebing Li; Gang Chen; Hongyu Liu; Qinghua Zhou; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-02-21       Impact factor: 4.147

9.  Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells.

Authors:  Ritsuko Harigai; Shigeki Sakai; Hiroyuki Nobusue; Chikako Hirose; Oltea Sampetrean; Noriaki Minami; Yukie Hata; Takashi Kasama; Takanori Hirose; Toshiki Takenouchi; Kenjiro Kosaki; Kazuo Kishi; Hideyuki Saya; Yoshimi Arima
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

Review 10.  Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review.

Authors:  Catherine Copley-Merriman; Xiaoqin Yang; Melissa Juniper; Suvina Amin; Hyun Kyoo Yoo; Shuvayu S Sen
Journal:  Adolesc Health Med Ther       Date:  2021-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.